LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-20
Case ID: NM_000546.5_c.854A_T_20261120_172727
Framework: ACMG/AMP 2015
Variant classification summary

NM_000546.5:c.854A>T

TP53  · NP_000537.3:p.(Glu285Val)  · NM_000546.5
GRCh37: chr17:7577084 T>A  ·  GRCh38: chr17:7673766 T>A
Gene: TP53 Transcript: NM_000546.5
Final call
Pathogenic
PS2 strong PS3 strong PM2 supporting PP3 moderate
All criteria require review: For research and educational purposes only.
Gene
TP53
Transcript
NM_000546.5
Protein
NP_000537.3:p.(Glu285Val)
gnomAD AF
0.0 (v4.1)
ClinVar
Pathogenic
OncoKB
Oncogenic
Interpretation summary
Generated evidence synthesis
1
Pathogenic: PS2 Strong reflects 4 de novo points from two strongly associated childhood cancers.
2
Pathogenic: PS3 Strong reflects non-functional Kato results and loss of function in three other eligible assays.
3
Pathogenic: PM2 Supporting reflects 0/1,614,150 alternate alleles in gnomAD v4.1.
4
Pathogenic: PP3 Moderate reflects VCEP Class C65 and BayesDel 0.453942.
Final determination: Under the ClinGen TP53 Expert Panel Version 2.4 point-based framework, PS2 Strong (+4) plus PS3 Strong (+4), PM2 Supporting (+1), and PP3 Moderate (+2) total 11 points, meeting the Pathogenic threshold of at least 10 points.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: c.854A>T is missense p.Glu285Val, whereas TP53 PVS1 applies to specified null or canonical splice variants.
cspec vcep_pvs1_flowchart vcep_pvs1_splicing_worksheet
PS1 Not assessed Not assessed: no previously VCEP-established pathogenic TP53 variant with the same amino-acid change as p.Glu285Val was identified.
cspec PMID:18762572 PMID:22507745
PS2 Met Met at strong: two strongly associated childhood cancers contribute 4 PS2 points under the assumed-parentage path, meeting the VCEP's 4-7-point PS2 threshold.
cspec vcep_table_of_lfs_cancers_and_points_for_ps2_and_pp1_code_application PMID:18762572 PMID:25584008
PS3 Met Met at strong: the VCEP worksheet pre-assigns PS3 because E285V is non-functional in Kato and LOF in three other eligible assays.
cspec vcep_flowchart_for_application_of_functional_rule_codes vcep_functional_worksheet PMID:18762572 PMID:25584008
PS4 Not met Not met: the documented Revised Chompret observation contributes 0.5 PS4 points, below the VCEP Supporting threshold of 1-1.5 points.
cspec vcep_ps4_points_table PMID:18762572 PMID:25584008 PMID:20436704 PMID:32113465 PMID:36970330
PM1 Not assessed Not assessed: residue 285 is outside the six listed codons, while the Cancer Hotspots same-change count needed for the alternative route is unavailable.
cspec hotspots
PM2 Met Met at supporting: gnomAD v4.1 reports AF 0 (0/1,614,150 alleles), below the VCEP PM2 threshold of <0.00003.
cspec gnomad_v4
PM3 N/A Not applicable: the TP53 VCEP CSPEC explicitly marks PM3 "Not Applicable".
cspec
PM4 N/A Not applicable: the TP53 VCEP marks PM4 Not Applicable, and c.854A>T is a missense substitution without a protein-length change.
cspec
PM5 Not assessed Not assessed: no different residue-285 missense variant was established as pathogenic or clinically supported likely pathogenic under the TP53 VCEP rules.
cspec pm5_candidates PMID:22507745
PM6 N/A Not applicable: the TP53 VCEP dropped PM6 and requires de novo evidence to be evaluated exclusively through PS2.
cspec
PP1 Not assessed Not assessed: no affected-relative segregation data or countable meioses are reported, so none of the VCEP's 3-4, 5-6, or ≥7-meiosis thresholds can be evaluated.
cspec vcep_table_of_lfs_cancers_and_points_for_ps2_and_pp1_code_application PMID:18762572
PP2 N/A Not applicable: the TP53 VCEP explicitly marks PP2 as Not Applicable.
cspec
PP3 Met Met at moderate strength: VCEP Table S2 pre-assigns PP3_moderate for Class C65 and BayesDel 0.453942, exceeding the ≥0.16 threshold.
cspec vcep_pp3_bp4_codes vcep_flowchart_for_application_of_pp3_2c_bp4_2c_and_bp7 spliceai
PP4 Not met Not met: the reported VAF is 38%, outside the VCEP PP4 Supporting range of 5-35% and without two 5-25% observations.
cspec PMID:36970330
PP5 N/A Not applicable: the TP53 VCEP explicitly designates PP5 as Not Applicable.
cspec
BA1 Not met Not met: gnomAD v4.1 reports AF 0 (0/1,614,150 alleles), far below the VCEP BA1 threshold of FAF ≥0.001.
cspec gnomad_v4
BS1 Not met Not met: gnomAD v4.1 reports AF 0 (0/1,614,150 alleles), below the VCEP BS1 range of FAF ≥0.0003 and <0.001.
cspec gnomad_v4
BS2 Not assessed Not assessed: no qualifying count of unrelated cancer-free females aged ≥60 years from one source is available for the VCEP BS2 rule.
cspec
BS3 Not met Not met: the VCEP worksheet assigns PS3 because E285V is non-functional in Kato and LOF in three other eligible assays, not benign functional evidence.
cspec vcep_flowchart_for_application_of_functional_rule_codes vcep_functional_worksheet PMID:18762572
BS4 Not assessed Not assessed: no affected family member with an LFS-associated cancer is documented as variant-negative, which is required for the VCEP BS4 rule.
cspec vcep_table_of_lfs_cancers_and_points_for_ps2_and_pp1_code_application PMID:18762572
BP1 N/A Not applicable: the TP53 VCEP explicitly marks BP1 as Not Applicable.
cspec
BP2 N/A Not applicable: the TP53 VCEP CSPEC explicitly marks BP2 "Not Applicable".
cspec
BP3 N/A Not applicable: the TP53 VCEP marks BP3 Not Applicable, and p.Glu285Val is a missense substitution rather than a repeat-region in-frame deletion.
cspec
BP4 Not met Not met: VCEP Table S2 classifies the missense variant as C65 with BayesDel 0.453942, while BP4 excludes C65 and requires BayesDel <0.16.
cspec vcep_pp3_bp4_codes vcep_flowchart_for_application_of_pp3_2c_bp4_2c_and_bp7 spliceai
BP5 N/A Not applicable: the TP53 VCEP explicitly designates BP5 as Not Applicable.
cspec
BP6 N/A Not applicable: the TP53 VCEP explicitly designates BP6 as Not Applicable.
cspec
BP7 N/A Not applicable: BP7 covers synonymous or intronic variants, whereas c.854A>T is a missense substitution producing p.Glu285Val.
cspec vcep_flowchart_for_application_of_pp3_2c_bp4_2c_and_bp7
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.